University of Dublin, Trinity College
tcd.ieTotal trials
73
Active
14
Phase 3
4
Total enrollment
8,094
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Methylphenidate | — | — | — | — | — | 1 | |
| Horizontal platelet-rich fibrin | — | — | — | — | — | 1 |
Next readouts
- 2026-06
- 2026-06-01
Top conditions
- Cancer8
- Multiple Sclerosis3
- Esophageal Cancer3
- Gastric Cancer3
- Schizophrenia3
- Spondylitis, Ankylosing2
- Circadian Rhythm Disorders2
- Amyotrophic Lateral Sclerosis2
Frequently asked questions about University of Dublin, Trinity College
- How many clinical trials does University of Dublin, Trinity College have on ClinicalTrials.gov?
- University of Dublin, Trinity College is listed as the lead sponsor on 73 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Dublin, Trinity College's trials are in Phase 3?
- 4 of University of Dublin, Trinity College's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University of Dublin, Trinity College focus on?
- University of Dublin, Trinity College's most-studied conditions on ClinicalTrials.gov are Cancer, Multiple Sclerosis, Esophageal Cancer, Gastric Cancer, Schizophrenia.
- When are University of Dublin, Trinity College's next clinical trial readouts?
- University of Dublin, Trinity College has 2 upcoming primary-completion readouts tracked here; the soonest is “Towards an Understanding of the Mechanism of Action of Methylphenidate in ADHD”, expected around 2026-06.